Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

News & Events

DETECT Schools Program Underway

The DETECT Schools program is underway, with swabs taken at 13 of the participating schools across Western Australia. No asymptomatic COVID-19 has been detected to date.

News & Events

Antiviral drug shown to speed up COVID-19 recovery

An international research collaboration, including The Kids Research Institute Australia infectious disease specialist Tobias Kollmann, has shown that the antiviral drug Interferon can speed up the recovery of COVID-19 patients.

News & Events

Home participation resource for children with disability and complex needs

For families with a child with disability, this involves many extra care duties especially if their child has high and complex needs.

Research

UV light and COVID-19

Investigator: Nisali Gamage Project description We critically review new studies which are emerging that report findings related to the effects of UV

News & Events

New research prepares for COVID-19 vaccine roll-out

As the world waits for a COVID-19 vaccine Perth researchers are getting one step ahead – embarking on a new study designed to prepare parents and government for a potential Australia-wide vaccination program.

News & Events

Trial tests which COVID-19 booster combos ‘boost’ immunity

MEDIA ENQUIRIES Discover. Prevent. Cure. Mailing list Media contacts About The Kids Be Inspired Please direct general enquiries to our reception on (

Research

Nudging towards COVID-19 and influenza vaccination uptake in medically at-risk children: EPIC study protocol of randomised controlled trials in Australian paediatric outpatient clinics

Children with chronic medical diseases are at an unacceptable risk of hospitalisation and death from influenza and SARS-CoV-2 infections. Over the past two decades, behavioural scientists have learnt how to design non-coercive 'nudge' interventions to encourage positive health behaviours. Our study aims to evaluate the impact of multicomponent nudge interventions on the uptake of COVID-19 and influenza vaccines in medically at-risk children.

Research

The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocol

Coronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended. 

Research

The Platform Trial In COVID-19 priming and BOOsting : The immunogenicity, reactogenicity, and safety of licensed COVID-19 vaccinations administered as a second booster in BNT162b2

PICOBOO is a randomised, adaptive trial evaluating the immunogenicity, reactogenicity, and safety of COVID-19 booster strategies. Here, we present data for second boosters among individuals aged 18-<50 and 50-<70 years old primed with BNT162b2 until Day (D) 84.

Research

Statistical considerations for the platform trial in COVID-19 vaccine priming and boosting

The Platform trial In COVID-19 priming and BOOsting (PICOBOO) is a multi-site, adaptive platform trial designed to generate evidence of the immunogenicity, reactogenicity, and cross-protection of different booster vaccination strategies against severe acute respiratory syndrome coronavirus 2 and its variants, specific for the Australian context.